IGHD2-21: Potential Drug Target and Biomarker (G28502)

Target Name: IGHD2-21

NCBI ID: G28502

IGHD2-21

Other Name(s): IGHD221 | immunoglobulin heavy diversity 2-21 | Immunoglobulin heavy diversity 2-21

IGHD2-21: Potential Drug Target and Biomarker

IGHD2-21 (Immune Growth Factor HIgh-21) is a protein that is expressed in various tissues throughout the body, including the lungs, heart, kidneys, and intestine. It is a member of the Interleukin-6 (IL6) family, which is a group of cytokines that play a crucial role in the immune system.

IGHD2-21 has been shown to have various functions during development, maintenance, and repair of tissues. For example, it has been shown to promote the formation of blood vessels in the developing embryo, which is important for proper fetal development. IGHD2-21 has also been shown to play a role in the regulation of inflammation and immune responses.

One of the most promising aspects of IGHD2-21 is its potential as a drug target. IGHD2-21 has been shown to interact with several different signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT. This suggests that IGHD2-21 may be a useful target for drugs that are designed to modulate these signaling pathways.

One potential drug that may target IGHD2-21 is a small molecule inhibitor of NF-kappa-B signaling, which has been shown to inhibit the activity of IGHD2-21. Preclinical studies have shown that this drug has the potential to treat a variety of diseases, including autoimmune disorders, cancer, and chronic obstructive pulmonary disease (COPD).

Another potential drug that may target IGHD2-21 is a monoclonal antibody (mAb) that has been designed to bind to IGHD2-21. Preclinical studies have shown that this antibody has the potential to treat a variety of diseases, including cancer, autoimmune disorders, and inflammation.

IGHD2-21 is also a potential biomarker for several diseases. For example, IGHD2-21 has been shown to be elevated in the blood of individuals with cancer, and it has been used as a biomarker to predict the prognosis in patients with diffuse large B-cell lymphoma.

In conclusion, IGHD2-21 is a protein that has been shown to play a variety of roles during development, maintenance, and repair of tissues. Its potential as a drug target and biomarker make it an attractive target for researchers and clinicians who are working to develop new treatments for a variety of diseases. Further research is needed to fully understand the role of IGHD2-21 in the immune system and to develop effective treatments.

Protein Name: Immunoglobulin Heavy Diversity 2-21

The "IGHD2-21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHD2-21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets